Christopher Ryan Sullivan - 09 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer Zoltoski, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
09 Jun 2023
Net transactions value
+$1,748
Form type
4
Filing time
13 Jun 2023, 16:41:21 UTC
Previous filing
17 May 2023
Next filing
14 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $1,748 +511 +68% $3.42* 1,262 09 Jun 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.